There is an all-hands-on-deck effort by drugmakers to produce more weight-loss medications, but a shortage could continue into 2025. NBC’s Christine Romans reports for TODAY on how companies are trying to keeping up with demand.
Drugmaker Eli Lilly said on Thursday it was suing six more entities including medical spas and wellness centers for selling products claiming to contain tirzepatide, the active ingredient in its popular diabetes drug, Mounjaro. Tirzepatide was approved late last year as Zepbound for weight loss, and Lilly is the only company that has the approval of the U.S. Food and Drug Administration to sell the drug.
Some doses of Mounjaro and Zepbound are expected to be available in limited quantities through the second quarter, according to the FDA. Lilly and Danish rival Novo have sued several entities to stop them from selling products claiming to contain the active ingredients — tirzepatide and semaglutide — used in their respective popular weight-loss drugs.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
2025 Polestar 3, 2025 BMW M2: This Week's Top PhotosPolestar's Cayenne rival, BMW's updated M2, and the final Nissan GT-R all made headlines today.
Read more »
MSGM Men’s Spring 2025, Women’s Resort 2025: The Kids Are More Than AlrightWith his MSGM men’s spring 2025, women’s resort 2025 collections Massimo Giorgetti celebrated color, energy, lightheartedness with a sea theme.
Read more »
Courrèges Men’s Spring 2025, Women’s Resort 2025: Diving Back Into SummerCourrèges men's spring 2025, women's resort 2025 ready-to-wear runway, fashion show & collection review. Nicolas Di Felice was fantasizing about summer in Greece after a 'never-ending winter.'
Read more »
Courrèges Spring 2025 Men’s and Women’s Resort 2025 Ready-to-Wear CollectionCourrèges Spring 2025 ready-to-wear fashion presentation & collection photos. Designed by Nicolas Di Felice at Paris Fashion Week Men’s, June 2024.
Read more »
Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supplyDemand for the drugs Mounjaro and Zepbound has far outpaced supply over the last year, forcing Eli Lilly to invest heavily to scale up its manufacturing.
Read more »
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, MounjaroEli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro. The drugmaker said Friday that it was more than doubling its investment in a site near its Indianapolis headquarters.
Read more »